SAN DIEGO (January 8, 2019)—ResMed a provider of respiratory care medical devices and out-of-hospital care software, announced that its portable oxygen concentrator, Mobi, is now widely available in the United States.

Mobi offers a balance of oxygen delivery, weight and battery life for people who are on the go with chronic obstructive pulmonary disease (COPD) or other chronic diseases.

SAN DIEGO (December 4, 2018)—ResMed, a provider of cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, announced it has entered a definitive agreement to acquire Propeller Health, a digital therapeutics company providing connected health solutions for people living with chronic obstructive pulmonary disease (COPD) and asthma.

AMSTERDAM (November 12, 2018)—Royal Philips announced the launch of a global initiative to celebrate everyday wins by patients, providers and caretakers regarding the management of chronic obstructive pulmonary disease (COPD). Launching on World COPD Day November 21, this awareness and celebratory campaign aims to help inspire COPD patients and their caregivers around ways to improve their overall quality of life.  

AMSTERDAM (October 30, 2018)—Royal Philips, a provider of health technology, announced the U.S. launch of InnoSpire Go, Philips’ smallest and lightest portable hand-held nebulizer system designed to deliver medication in just four minutes, reducing treatment time by up to 25 percent. The easy-to-use and virtually silent InnoSpire Go puts hospital-grade nebulizer technology into the hands of the user for portable, fast and effective medication delivery.

Research in noninvasive ventilation for COPD treatment.

NEW YORK (February 12, 2018)—Jeremy Orr, MD, of University of California, San Diego, has been awarded the new ATS Foundation/ResMed Research Fellowship in Noninvasive Ventilation (NIV) in COPD.

ResMed is a provider of NIV devices for treating COPD (chronic obstructive pulmonary disease) in the home and hospital.

Dr. Orr’s $100,000 award will support his research focused on the impact of noninvasive ventilation on cardiovascular biomarkers in COPD.

Philips pledges $1 for every social share of campaign videos during November.

AMSTERDAM (November 14, 2017)—Ahead of World COPD Day on November 15, Royal Philips announced the launch of a global movement to raise awareness for chronic obstructive pulmonary disease (COPD). COPD is the fourth leading cause of death worldwide and is estimated to be the third leading cause by 2020, but there is a lack of awareness and social stigma associated with the disease. Only about half of the estimated 210 million people with the disease have been officially diagnosed.

Philips study shows 92 percent of patients are not receiving PAP therapy.

TUCSON, Ariz. (July 10, 2017)—COPD hospitalizations are at an all-time high. The 30-day readmission rate for patients ranges from 20 to 39 percent, with related health care costs at an estimated $50 billion. A recently published study, funded by Royal Philips, revealed that although positive airway pressure (PAP) therapy was associated with a reduction in hospitalization, more than 92 percent of patients studied were not receiving it in any form.

The study found increases in quality of life for patients on home therapies.

AMSTERDAM (May 22, 2017)—Recently published advancements in pulmonary research suggest that the combination of non-invasive ventilation (NIV) and home oxygen therapy (HOT) can significantly prolong time to readmission or death for patients with chronic obstructive pulmonary disease (COPD) following a life-threatening respiratory event or exacerbation.